Member Info for TorquayFan

Thanks for passing that on researcher1. Nothing untoward in the comment and I take it at face value.
Very interesting and good to see a bit of optimism around . . . .

BTW I see you don't post much on SCLP but very well done with that average !

I heard a Grand Challenge comment on the 'Today' programme. As per CRUK website - that was one of 4 x £20 million winners in 2017 !! Let's hope CRUK have got another £80 million at the ready right now LOL !

Fingers crossed. Crumbs - re the Guardian. No mention of Scancell - maybe Scancell will get into the radar in January ?

Hope you Guys had a nice Christmas Day.

Keytruda as a mono therapy ''demonstrated a significant improvement in overall survival compared with chemotherapy.'' The SCIB2 Combo trial at CRUK will be interesting . . .

''US-based Merck & Co is asking the FDA to review Keytruda (pembrolizumab) as a monotherapy for certain untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC). At least 1% of tumour cells must express the biomarker PD-L1, and patients must not have the EGFR or ALK mutations. Merck’s filing is based on results from the phase 3 KEYNOTE-042 trial, where Keytruda monotherapy demonstrated a significant improvement in overall survival compared with chemotherapy in this patient group.''

https://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/?

Keytruda as a mono therapy ''demonstrated a significant improvement in overall survival compared with chemotherapy.'' The SCIB2 Combo trial at CRUK will be interesting . . . .

''US-based Merck & Co is asking the FDA to review Keytruda (pembrolizumab) as a monotherapy for certain untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC). At least 1% of tumour cells must express the biomarker PD-L1, and patients must not have the EGFR or ALK mutations. Merck’s filing is based on results from the phase 3 KEYNOTE-042 trial, where Keytruda monotherapy demonstrated a significant improvement in overall survival compared with chemotherapy in this patient group.''

https://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/?

Keytruda as a mono therapy ''demonstrated a significant improvement in overall survival compared with chemotherapy.'' The SCIB2 Combo trial at CRUK will be interesting . . . .

''US-based Merck & Co is asking the FDA to review Keytruda (pembrolizumab) as a monotherapy for certain untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC). At least 1% of tumour cells must express the biomarker PD-L1, and patients must not have the EGFR or ALK mutations. Merck’s filing is based on results from the phase 3 KEYNOTE-042 trial, where Keytruda monotherapy demonstrated a significant improvement in overall survival compared with chemotherapy in this patient group.''

https://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/?

Ray I hope you don't mind but I've noted your 09.32 on the other side - it would be good to see some more comments. ATB

Thanks Ray - well spotted indeed. Has page 38 been added since AGM ?

After you get some more reactions, can you take a punt on what this means commercially? I guess at least it brings Scancell and BioNTech/Genetech closer ?

Again thanks and wishing you a Happy Christmas - you have been the STAR addition to the BB this year - no doubt of that. ATB

''Checkpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval for even earlier use of its Keytruda product in Europe. The European Medicines Agency has approved PD-1 inhibitor Keytruda (pembrolizumab) as an adjuvant therapy for adults who have undergone surgery to remove melanoma, based on clinical results showing it can reduce the risk of the cancer returning.''

https://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/?

C7. The 'other' site has SP at 8 pence having gone up from 7.5 pence. This site 7.8 pence. What ?
Good luck this week and hope for the best Christmas for you.

Hanoi - found it. LOTS of posts on there ! ATB

RP - thanks. If I remember, this time I typed 'TT' in the header of the open Twitter page and it appeared with the link ok. and 'tt' in the link. When I tried copying with 'tt' in place, it went wrong ! If I have time I usually test it on another Forum to check . . . Berm gave me the 'TT' tip and it often helps. But no accounting for it.

Much looking forward to the CRUK GC result in January. ATB

Hanoi - what's that about another SCLP BB ? Haven't seen it.

ATB

Or, waking up now, on bbc.co.uk/radio5live

That'll be past my bedtime but I'll catch it later on bbc.co.uk/radio4 Thanks.

Here's to a blue week coming. GLA

https://twitter.com/CRUKresearch/status/1073935709252272128

Here it is :-

hTTps://twitter.com/CRUKresearch/status/1073935709252272128

?

Ivy - 'inclusive' indeed.

RW 13.55 Friday - a helpful tweet from Trinity Delta of that article in 'Nature'. How nice to see an 'International Journal of Science' current edition and a mention of Scancell ! More please . .
https://www.nature.com/articles/d41586-018-07645-x?

WF 14.05 Friday - thanks for that link. Will watch later. (BTW TUFC top the table).

MattR - 21.07 Friday - £2 would be a good start.

Me - a quiet week and SP langours still. Something special next week ? GLA

RR. Again ! OMG. 'Mai kao jai' most of your Wed 23.30 but I can comment on 'negative' and 'realistic'.

Negative (or positive) can be about - perception of the level of water in the bucket ? Geddit ?
And it's possible to be 'realistic' with optimism or 'realistic' with pessimism.

When I read your Wed 23.30 - you posted - ''For me, already past the point of selling. It either a recovery or a write off''. Ouch ! I thought you'd gone from - (yonks ago) - constructive poster - to cynic to - (nearly) - 'Tr*ll'.

Anyway, to spare the BB any more of this exchange - BFN Last to you FAW.

To cheer you up - is that possible ? Thursday 23.20 I posted some appreciation for a 'marketwatch'. (No space). It appeared on the BB with 4 x * amidst. I wondered why and asked Admin ?

BFN

In this article, ''The genetic shortcut to antibody drugs'' under a section ''It's all in the delivery'' - our dear 'ole Scancell actually gets a mention . . . . .

''Scancell, a cancer-immunotherapy company in Oxford, UK, has used electroporation to transfer a gene encoding a lab-designed antibody that primes immune cells called T cells to target tumours in people with melanoma. In 2017, the company reported that the treatment safely induced an immune response against the cancer.''

https://www.nature.com/articles/d41586-018-07645-x?

Nice link from Bermuda so thanks to him. GLA

Good to see you posting C7 - I enjoy the market watch and the optimism, from you and Crumbs etc.

And I'll join RR in wishing for this : ''News that the FDA issue has been resolved and trials WILL start as planned''. That would be a nice Christmas present . . .

The discussion about TriGrid V1 or V2 was constructive. Posters worked with each other and in the end, it was confirmed that as yet, a Study in the USA using V2 had not been found atm. Study 6 of the 14 in the link which commenced only a few weeks ago, Sep 17th, was using the V1, confirming WF and Inan position. Bermuda noted the comments of Dr Sally at the AGM 24 mins 25 secs which confirmed that Scancells IND includes the use of TriGrid2.

https://drive.google.com/file/d/12QRlLjAojWKukLipQ4_1MkpOZOUTjHoJ/view

(I was travelling yesterday - Chantaburi - Chiang Mai - a long drive. Just noticed your Wed 11.30 pm. I wondered what the point of your post was as I had conceded ambiguity before ? Then I saw your negative conclusion with which I don't agree although I am similarly impatient for a better SP. IMO there's lots of reasons for Scancell holders to be optimistic and I'm not alone in that).

ATB

On topic Nom !
Nice link . . .